☞ 우리 가 살 면서 한 두 번 ' 두통 ' 을 앓 아 보 지 않 은 사람 은 없 을 것 이 다 . 문제 는 편두통 ( migraine ) 을 단순 한 두통 ( headaches ) 으로 착각 하 는 것 . 약국 이나 병원 에 들러 ' 진통제 '( painkillers ) 를 처방 받 고 그냥 견딘다는 말 이 다 . 진단 결과 ' preventive ' 라면 다행 이 지만 ' acute pain '( 격통 ) 이 면 평생 동안 정신병 을 안 고 살 아야 만 한다 . ( neuropsychiatric complaint ) . . 특히 어린이 의 경우 ' 정신 적 학대 '( emotional abuse ) 를 받 았 을 경우 에 육체 적 고통 ( physical abuse ) 이나 성폭행 ( sexual abuse ) 보다 ' 평생 고질병 ( 55 %)' 으로 고생 을 한다 ' 는 보고 가 있 다 . - ( 오하 이 오 톨 리도 대학 ) 대상 은 넘 녀 노소 누구 나 , 특히 여성 들 에게 심하 다 . 증상 으로 는 ' 어지러움 증 '( dizziness ) , ' 메스꺼움 '( nausea ) , ' 격심 한 통증 '( crippling pain ) , ' 토사 '( vomiting ) 증상 이 있 다 . 원인 은 ' 열악 한 환경 ' 으로 인해 월 2 ~ 3 회 반복 적 으로 지속 되 며 목 . 어깨 등 으로 번져나간다 . . ' 유전 적 ' 으로 전파 되 는 경우 도 있 지만 ( hereditary ) 이 들 에게 는 특히 ' 음식 . 술 . 커피 . 쵸 코 릿 . 매연 및 화학 물질 냄새 나 주위 의 소음 에 매우 민감 하 다 ( sensitivity to ) . 예방법 으로 는 ' 까마귀 노니 는 데 백로 가 가 지 말 아야 한다 . '..' 청결 하 고 규칙 적 인 생활 습관 ' 이 필수 다 . ( sound & hygiene & regular life style ) ▶ 어린이 편두통 . 우울증 환자 급증 어린 시절 에 주먹 으로 맞 거나 발 로 차이 거나 우연 한 사고 로 인해 벽 에 부딪히 거나 계단 에서 넘어져 굴러 떨어지 거나 하 는 것 은 ' physical abuse ' 다 . 그런데 어린이 에게 치명상 은 정신 적 으로 왕따 를 시키 며 괴롭히 는 행위 는 ' emotional abuse ' 다 . 14 , 484 명 의 두 통 환자 를 대상 으로 ( 24 ~ 32 세 ) 실험 한 결과 14 % 의 환자 는 심한 ' 편두통 환자 ' 로 판명 되 었 다 . 이 들 중 47 % 는 ' 정신 적 학대 ' 경험 을 , 18 % 는 ' 육체 적 학대 ' 를 , 5 % 는 ' 성폭행 ' 경험 자 들 이 다 . 편두통 환자 의 61 % 는 어린 시절 에 ' 정신 적 학대 ' 를 , 49 % 는 그렇 지 않 았 던 환자 들 이 었 다 . " 확률 적 으로 는 정신 적 학대 를 받 았 던 어린이 ' 3 명 중 1 명 '( 32 %) 은 성인 이 되 어 학대 받 지 않 은 사람 보다 편두통 을 앓 을 수 있 다 ".- Dr . 테 에 티 엔 . 주 ; " 편두통 의 원인 은 ' oxidative stress 라는 스트레스 호르몬 의 불 균형 ' 인데 아직 까지 ' 만병통치약 ' 은 없 다 . 하지만 비타민 처럼 복용 할 날 도 . ."▶ 3 년 내 편두통 신약 개발 예정 이름 하 여 ' ALD 403 '..' 75 % 완치 가능 '-' 획기 적 이 다 '. 현재 4 개 회사 가 경합 중 ; 선두 주자 는 ' Alder BioPhamaceutical Inc . '-' Amgen , Eli Lilly , Teva . ." 타 회사 는 1 년 에 4 번 주사 , 우리 는 1 번 으로 끝 " - Alder 사 의 CEO 가 한 말 이 다 . " 2019 년 에 제조 면허 허가 '( licencing appiications ) 를 신청 . 획득 할 것 이 다 . ".. 이 들 제 조사 들 의 주 목적 은 ' 유전자 관련 팹 티 드 - 양 뇌 의 신경 세포 혈관 을 확장 시키 는 아미노산 > 를 씻 어 내 는 ( mop up ) 것 이 었었 다 . 결과 는 ' 간 손상 '( liver damage ) 만 초래 시킬 뿐 CGRP 단백질 항체 ( antibody ) 를 제거시키 지 못하 는 결과 를 가져 왔 다 . 방법 은 피하 주사 ( jab ) . 그것 도 ' 1 년 에 한 번 주사 ' 로 ( one time injection - period ) . . 시장 규모 는 전 세계 약 ' 60 억 파운드 '. 경쟁사 들 도 ' exciting landmark '.▣ [ English Review ] ' 모든 사물 을 살펴보 는 지혜 를 ( check - out ) , . 해 봐야 무슨 소용 이 있 는가 ? ( What ' s the point in doing ~), . 그래도 되게 하 라 . ( to make it work ) ' A ; I still want to look into ( check out ) the next store for dresses . B : I understand , but I ' m not sure if we have enough time for that . A ; I ' ve given up on asking Ashley out . ( 애슐리 에게 데이트 신청 포기 했 어 ) . . B ; Why did something happen ? .. A ; No , that ' s the problem . I texted her three times , but she hasn ' t answered . What ' s the point in trying if she won ' t even get back to me ? ( 나 한테 대꾸 도 안 하 는데 ) A ; The studio can ' t have this many extra invitations ready by tomorrow . . B ; That ' s no good . Is there any way they can make it work ? ( Is there any way they can make it happen ? ) . . A ; I ' ll talk to them again . Let me see what I can do . ( Let me see if how it can work ) . Emotional abuse in childhood can lead to migraines later in life : HALF of sufferers studied were treated badly as childrenThe study included data from 14 , 484 people and 14 % had migrainesPeople emotionally abused as children were 52 % more likely to sufferThe link between migraine and abuse was stronger for emotional abuse than for physical or sexual abuse in the studyMore research is needed to establish the underlying cause of this linkBy VICTORIA WOOLLASTON FOR MAILONLINEPUBLISHED : 21 : 00 GMT , 2 March 2016 | UPDATED : 06 : 23 GMT , 3 March 2016 Researchers have found a ' significant ' link between emotional abuse in a person ' s formative years and the chances of them suffering from migraines as an adult . People who were abused , emotionally , physically or sexually , were 55 per cent more likely to have migraines than those who were never abused . But , narrowing the results further , people who were emotionally abused were 52 per cent more likely to have migraines . In fact , the link between migraine and abuse was stronger for emotional abuse than for physical or sexual abuse in the study . ' Emotional abuse showed the strongest link to increased risk of migraine , ' said author Gretchen Tietjen from the University of Toledo in Ohio . ' Childhood abuse can have long - lasting effects on health and well - being . ' In the study , emotional abuse was assessed by asking : ' How often did a parent or other adult caregiver say things that really hurt your feelings or made you feel like you were not wanted or loved ? ' The study included data from 14 , 484 people age 24 to 32 . About 14 per cent reported they had been diagnosed with migraines . WHAT CAUSES MIGRAINES ? Migraines have a single cause that is to blame for every symptom ranging from pain to nausea , a recent study claimed . Scientists found that a surplus of free radicals , the corrosive molecules produced by our bodies as we process oxygen , were at the root of all headaches . The surplus creates an imbalance in the body which is called ‘ oxidative stress ’, when there are not enough antioxidant defences to fend off the free radicals . The researchers said that their findings could one day help find a cure for migraines - which could be as simple as taking a vitamin . Physical abuse was defined as being hit with a fist , kicked , or thrown down on the floor , into a wall , or down stairs . Sexual abuse included forced sexual touching or sexual relations . About 47 per cent of the participants answered yes to having been emotionally abused , 18 per cent physically abused and 5 percent sexually abused . Of those diagnosed with migraines , 61 per cent said they had been abused as a child . Of those who never had a migraine , 49 per cent said they were abused . Those who were sexually or physically abused were not significantly more likely to have migraine than people who were not abused . The relationship between emotional abuse and migraine remained when researchers adjusted the results to take into account depression and anxiety . In that analysis , people who were emotionally abused were 32 percent more likely to have migraine than people who were not abused . Identifying migraines and how best to avoid themLoaded : 0 % Progress : 0 % 00 : 00 PlayMuteCurrent Time 0 : 00 / Duration Time 1 : 52 FullscreenNeed Text + 2 Emotional abuse was assessed by asking : ' How often did a parent or other adult caregiver say things that really hurt your feelings or made you feel like you were not wanted or loved ? '. The link between emotional abuse and migraines remained when researchers took into account depression and anxiety . Stock imageTietjen noted that the study shows an association between childhood emotional abuse , a very common occurrence , and migraine . It does not show cause and effect , although the finding that the likelihood of having migraines increases with increasing number of abuse types is suggestive of it . ' More research is needed to better understand this relationship between childhood abuse and migraine , ' said Tietjen . ' This is also something doctors may want to consider when they treat people with migraine . ' The jab that could end the misery of migraines : New ' holy grail ' drug slashes the number of attacks by up to 75 % In a trial of 600 people , the drug , code - named ALD 403 , significantly slashed attacks in a third of patients , pharmaceutical company claimsIf further trials go well , drug could be available within three yearsUK migraine charity : ' This is a huge development for migraine sufferers ' By BEN SPENCER MEDICAL CORRESPONDENT FOR THE DAILY MAILPUBLISHED : 16 : 34 GMT , 4 April 2016 | UPDATED : 20 : 00 GMT , 4 April 2016 Millions of people who suffer migraines have finally been offered hope of an effective treatment , after trials showed that a new injection could prevent attacks . Three - quarters of those struck by attacks - which can trigger dizziness , nausea and crippling pain - are women . Although painkillers and other drugs can ease the symptoms , they do not work for everyone and as yet no drug has been found that can actually prevent the attacks . But early trials have now shown that a breakthrough drug can reduce the number of attacks by three quarters in some patients . Alder BioPharmaceuticals Inc said that in a trial of 600 people , its injection , code - named ALD 403 , slashed attacks by 75 per cent in a third of patients . + 2 Three - quarters of people struck by migraine attacks - which can trigger dizziness , nausea and crippling pain - are women . Now , a new injection could slash the number of attacks The firm , which saw its shares jump 50 per cent when it announced the results , hopes to make the drug available to patients in three years , if further trials go well . It is one of four major pharmaceutical firms racing to be the first to introduce the first drug specifically designed to treat migraines . Described as one of the few true ‘ holy grails ’ of medical research , an injection to truly tackle migraines is the being pursued by drugs giants Amgen , Eli Lilly and Teva , who are each competing with Alder to get the first licence for the medication . Alder chief executive Randall Schatzman said he hoped to submit licensing applications for public use in 2019 . ‘ We ’ re proposing that patients are dosed four times a year , ’ he said . ‘ Most other developers are looking at once - a - month dosing . ’ NextEach of the four companies are developing variants of a drug which tackles a protein called calcitonin gene - related peptide ( CGRP ) , which triggers the pain and nausea associated with a migraine . CGRP causes the swelling of blood vessels intertwined with nerve endings on both sides of the head . Researchers have found that monoclonal blood proteins – antibodies specifically engineered to bind to CGRP – were able to ‘ mop up ’ the chemical , meaning it did not trigger a migraine . Scientists realised the significance of CGRP in migraines in the 1980 s , but earlier trials were abandoned of fears that they caused liver damage . The latest batch of drugs have shown few safety issues , according to the trial results . Professor Peter Goadsby , trustee of the UK Migraine Trust , said : ‘ This is a huge development for migraine sufferers . There is no current specific treatment that has been developed for migraine . + 2 Each of the four companies are developing variants of a drug which tackles a protein called calcitonin gene - related peptide ( CGRP ) , which triggers the pain and nausea associated with a migraine ‘ The research has now come to a point where we understand the condition enough that we have worked out how to treat it . ‘ All the studies that have been done are positive , and there has been an almost - embarrassing lack of side effects . ‘ For a group of people who have never had a proper treatment , this is fantastic news . ’ Professor Goadsby , who is also director of the NIHR King ' s Clinical Research Facility in London , said the fact that several companies are pursuing the drug was very welcome . ‘ We have four companies charging along to develop this drug , which can only be a good thing . Competition can only push people along and push down prices . ’ This is a huge development for migraine sufferers . There is no current specific treatment that has been developed for migraine Professor Peter Goadsby , trustee of the UK Migraine Trust All four companies are close to or already have completed phase two trials - and are racing to be the first to complete final phase three trials and get a licence for the drugs - with analysts predicting the market could be worth £ 6 billion a year worldwide . Sean Harper , vice president of Amgen , said : ‘ I can think of only a few examples of holy grails in medicine , which have existed for thousands of years , and this is one of them . ’‘ There ’ s just no effective preventive therapy for migraine that ’ s worth taking , ’ he told the Financial Times . Eli Lilly is focusing on cluster headaches , a rarer condition , but one where there are even fewer effective treatments . It reported a significant reduction in the number of ‘ migraine days ’ reported by patients who took the drug last June . David Ricks , senior vice president of Eli Lilly , said : ‘ These results reinforce our confidence in the potential of this medicine to be a significant option for the preventive treatment of debilitating headache disorders like migraine and cluster headache . ’ Teva , an Israeli drugs company , reported similar results for its own drug in September . The firm ’ s vice - president Marcelo Bigal said : ‘ These findings constitute an exciting landmark in the development of migraine prevention treatment options . ’ What are migraines , and how can they be prevented ? Loaded : 0 % Progress : 0 % 00 : 00 PlayMuteCurrent Time 0 : 00 / Duration Time 3 : 27 FullscreenNeed TextEach of the four companies are developing variants of a drug which tackles a protein called calcitonin gene - related peptide ( CGRP ) , which triggers the pain and nausea associated with a migraine . CGRP causes the swelling of blood vessels intertwined with nerve endings on both sides of the head . Researchers have found that monoclonal blood proteins – antibodies specifically engineered to bind to CGRP – were able to ‘ mop up ’ the chemical , meaning it did not trigger a migraine . Scientists realised the significance of CGRP in migraines in the 1980 s , but earlier trials were abandoned of fears that they caused liver damage . The latest batch of drugs have shown few safety issues , according to the trial results . Professor Peter Goadsby , trustee of the UK Migraine Trust , said : ‘ This is a huge development for migraine sufferers . There is no current specific treatment that has been developed for migraine . + 2 Each of the four companies are developing variants of a drug which tackles a protein called calcitonin gene - related peptide ( CGRP ) , which triggers the pain and nausea associated with a migraine ‘ The research has now come to a point where we understand the condition enough that we have worked out how to treat it . ‘ All the studies that have been done are positive , and there has been an almost - embarrassing lack of side effects . ‘ For a group of people who have never had a proper treatment , this is fantastic news . ’ Professor Goadsby , who is also director of the NIHR King ' s Clinical Research Facility in London , said the fact that several companies are pursuing the drug was very welcome . ‘ We have four companies charging along to develop this drug , which can only be a good thing . Competition can only push people along and push down prices . ’ This is a huge development for migraine sufferers . There is no current specific treatment that has been developed for migraine Professor Peter Goadsby , trustee of the UK Migraine Trust All four companies are close to or already have completed phase two trials - and are racing to be the first to complete final phase three trials and get a licence for the drugs - with analysts predicting the market could be worth £ 6 billion a year worldwide . Sean Harper , vice president of Amgen , said : ‘ I can think of only a few examples of holy grails in medicine , which have existed for thousands of years , and this is one of them . ’‘ There ’ s just no effective preventive therapy for migraine that ’ s worth taking , ’ he told the Financial Times . Eli Lilly is focusing on cluster headaches , a rarer condition , but one where there are even fewer effective treatments . It reported a significant reduction in the number of ‘ migraine days ’ reported by patients who took the drug last June . David Ricks , senior vice president of Eli Lilly , said : ‘ These results reinforce our confidence in the potential of this medicine to be a significant option for the preventive treatment of debilitating headache disorders like migraine and cluster headache . ’ Teva , an Israeli drugs company , reported similar results for its own drug in September . The firm ’ s vice - president Marcelo Bigal said : ‘ These findings constitute an exciting landmark in the development of migraine prevention treatment options . ’ What are migraines , and how can they be prevented ? Loaded : 0 % Progress : 0 % 00 : 00 PlayMuteCurrent Time 0 : 00 / Duration Time 3 : 27 FullscreenNeed TextRead more : http : / / www . dailymail . co . uk / health / article - 3522964 / The - jab - end - misery - migraines - New - drug - slashes - number - attacks - 75 . html # ixzz 44 uRHRwUL Follow us : @ MailOnline on Twitter | DailyMail on FacebookEach of the four companies are developing variants of a drug which tackles a protein called calcitonin gene - related peptide ( CGRP ) , which triggers the pain and nausea associated with a migraine . CGRP causes the swelling of blood vessels intertwined with nerve endings on both sides of the head . Researchers have found that monoclonal blood proteins – antibodies specifically engineered to bind to CGRP – were able to ‘ mop up ’ the chemical , meaning it did not trigger a migraine . Scientists realised the significance of CGRP in migraines in the 1980 s , but earlier trials were abandoned of fears that they caused liver damage . The latest batch of drugs have shown few safety issues , according to the trial results . Professor Peter Goadsby , trustee of the UK Migraine Trust , said : ‘ This is a huge development for migraine sufferers . There is no current specific treatment that has been developed for migraine . + 2 Each of the four companies are developing variants of a drug which tackles a protein called calcitonin gene - related peptide ( CGRP ) , which triggers the pain and nausea associated with a migraine ‘ The research has now come to a point where we understand the condition enough that we have worked out how to treat it . ‘ All the studies that have been done are positive , and there has been an almost - embarrassing lack of side effects . ‘ For a group of people who have never had a proper treatment , this is fantastic news . ’ Professor Goadsby , who is also director of the NIHR King ' s Clinical Research Facility in London , said the fact that several companies are pursuing the drug was very welcome . ‘ We have four companies charging along to develop this drug , which can only be a good thing . Competition can only push people along and push down prices . ’ This is a huge development for migraine sufferers . There is no current specific treatment that has been developed for migraine Professor Peter Goadsby , trustee of the UK Migraine Trust All four companies are close to or already have completed phase two trials - and are racing to be the first to complete final phase three trials and get a licence for the drugs - with analysts predicting the market could be worth £ 6 billion a year worldwide . Sean Harper , vice president of Amgen , said : ‘ I can think of only a few examples of holy grails in medicine , which have existed for thousands of years , and this is one of them . ’‘ There ’ s just no effective preventive therapy for migraine that ’ s worth taking , ’ he told the Financial Times . Eli Lilly is focusing on cluster headaches , a rarer condition , but one where there are even fewer effective treatments . It reported a significant reduction in the number of ‘ migraine days ’ reported by patients who took the drug last June . David Ricks , senior vice president of Eli Lilly , said : ‘ These results reinforce our confidence in the potential of this medicine to be a significant option for the preventive treatment of debilitating headache disorders like migraine and cluster headache . ’ Teva , an Israeli drugs company , reported similar results for its own drug in September . The firm ’ s vice - president Marcelo Bigal said : ‘ These findings constitute an exciting landmark in the development of migraine prevention treatment options . ’ What are migraines , and how can they be prevented ? Loaded : 0 % Progress : 0 % 00 : 00 PlayMuteCurrent Time 0 : 00 / Duration Time 3 : 27 FullscreenNeed Text 1 Previous 공유 하 기 글 요소